ExodusPoint Capital Management’s OnKure Therapeutics OKUR Stock Holding History

ExodusPoint Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-37,898	Closed	-$2.89M	–	2143
2023 Q3	$2.89M	Sell	37,898 -17,634	-32%	-$1.2M	0.03%	554
2023 Q2	$3.64M	Buy	55,532 +30,953	+126%	+$2.49M	0.03%	568
2023 Q1	$1.47M	Buy	24,579 +10,714	+77%	+$388K	0.01%	1005
2022 Q4	$323K	Buy	+13,865	New	+$368K	﹤0.01%	1329

Other funds holding OKUR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

ExodusPoint Capital Management's OKUR Position: Q4 2023 in Review

ExodusPoint Capital Management sold out of OnKure Therapeutics (OKUR) in Q4 2023, closing a stake of 37,898 shares — an estimated $2.89M sold.

ExodusPoint Capital Management first reported a position in OKUR in Q4 2022 and held it in 4 quarters. The position peaked at $3.64M in Q2 2023. 68 funds tracked by Wall St. Rank hold OKUR as of Q4 2023.

ExodusPoint Capital Management reported no remaining OnKure Therapeutics position as of Q4 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 37,898 OnKure Therapeutics shares in Q4 2023, an estimated $2.89M.
ExodusPoint Capital Management first reported a position in OnKure Therapeutics in Q4 2022 and held it in 4 quarters.
ExodusPoint Capital Management's OnKure Therapeutics position peaked at $3.64M in Q2 2023.
68 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2023.

Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.